SEC Tracker
Get the app

CRISPR Therapeutics CRSP

CRISPR Therapeutics Q2 FY24: revenue $517K; diluted EPS −$1.49

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers CRISPR Therapeutics reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$517KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$126.4MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$1.49No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$484.5MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$95.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when CRISPR Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float over $2B, nearest public float first, as each company reports it on its annual report cover.

  1. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  2. Halozyme Therapeutics HALO public float $4.5B, Jun 30, 2025
  3. Vaxcyte PCVX public float $3.7B, Jun 30, 2025
  4. Krystal Biotech KRYS public float $3.5B, Jun 30, 2025
  5. Arcellx ACLX public float $3.2B, Jun 30, 2025